Call us now0755-8668-0658 E-mailinfo@immuclin.com

Intorduction

Ovarian Cancer

Ovarian malignant tumor is one of the common malignant tumors of female reproductive organs, the incidence rate is second only to cervical cancer and uterine body cancer and ranks third. However, the mortality rate of epithelial ovarian cancer is the first among all types of gynecological tumors, posing a serious threat to women's lives. Because the embryonic development, tissue anatomy, and endocrine function of the ovary are complex, and the early symptoms are not typical, it is quite difficult to distinguish the tissue types and benign and malignant types of ovarian tumors before surgery. Epithelial cancer is the most common ovarian malignant tumor, followed by malignant germ cell tumors. In patients with epithelial ovarian cancer, only 30% of the tumors are found to be confined to the ovaries. Most of them have spread to the uterus, bilateral appendages, omentum and pelvic organs, so early diagnosis is a big problem.

Symptoms

Pain, irregular menstruation, weight loss



Lower abdomen mass

Ascites



Cachexia

ACTL Treatment Plan

After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:

1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.

2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.

3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108

4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.

5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment

After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:

1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.

2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.

3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108

4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.

5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment

After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:

1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.

2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.

3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108

4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.

5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment

  • I. Patients with stage II tumors

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

  • III. Patients with stage IV tumors

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

  • Patients who have finished radiotherapy and chemotherapy

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

  • Patients receiving radiotherapy and chemotherapy

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

  • Patients with severe disease and rapid progress

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

ACTL Case Studies

Expert Consultation